A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first-or second-line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive metastatic breast cancer (MBC) who have received trastuzumab and endocrine therapies

Trial Profile

A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first-or second-line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive metastatic breast cancer (MBC) who have received trastuzumab and endocrine therapies

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Lapatinib (Primary) ; Anastrozole; Exemestane; Letrozole; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTERNATIVE
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 31 May 2019 to 5 May 2019.
    • 16 Oct 2017 Planned primary completion date changed from 1 May 2019 to 5 May 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top